Annalisa JenkinsChief Executive Officer at PlaqueTec Ltd
Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of Global Research and Development and executive vice president of Global Development and Medical Affairs at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years, including head of Global Medical Affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and chairs or serves on the boards of a number of private and public biotech and life science companies. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital at the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.